{
  "source": "PA-Notification-Cerdelga.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1148-11\nProgram Prior Authorization/Notification\nMedications Cerdelga® (eliglustat)\nP&T Approval Date 12/2014, 11/2015, 9/2016, 9/2017, 9/2018, 9/2019, 9/2020, 10/2021,\n10/2022, 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nCerdelga® (eliglustat) is a glucosylceramide synthase inhibitor indicated for the long-term\ntreatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers\n(EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-\ncleared test. CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations of\nCerdelga to achieve a therapeutic effect. A specific dosage cannot be recommended for\nCYP2D6 indeterminate metabolizers.1\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Cerdelga will be approved based on both of the following criteria:\na. Diagnosis of Gaucher disease type 1\n-AND-\nb. Patient is one of the following as detected by an FDA-cleared test:\n(1) CYP2D6 extensive metabolizer\n(2) CYP2D6 intermediate metabolizer\n(3) CYP2D6 poor metabolizer\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Cerdelga will be approved based on the following criterion:\na. Documentation of positive clinical response to Cerdelga therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program.\n• Supply limits may be in place.\n3. References:\n1. Cerdelga [package insert]. Genzyme Irelan",
    "s codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program.\n• Supply limits may be in place.\n3. References:\n1. Cerdelga [package insert]. Genzyme Ireland, Ltd. Waterford, Ireland. January 2024.\nProgram Prior Authorization/Notification - Cerdelga (eliglustat)\nChange Control\n12/2014 New program.\n11/2015 Annual review. Updated to align with Indication Section of FDA label.\n9/2016 Annual review. No changes to coverage criteria.\n9/2017 Annual review. No changes.\n9/2018 Annual review. No changes.\n9/2019 Annual review. No changes to coverage criteria. Updated background\nand references.\n9/2020 Annual review. No changes to coverage criteria.\n10/2021 Annual review. Updated reauthorization duration. Updated reference.\n10/2022 Annual review. No changes to coverage criteria. Added state mandate.\nUpdated reference.\n10/2023 Annual review. No changes to coverage criteria. Updated reference.\n10/2024 Annual review. No changes to coverage criteria. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}